Skip to main content

Hepatitis C Treatment: Price, Profits, and Barriers to Access

The World Health Organization estimates that as many as 185 million people, or 3 percent of the world’s population, are infected with the hepatitis C virus. Though it is curable, the vast majority of people living with hepatitis C reside in low- and middle-income countries where treatment is virtually inaccessible.

The main medicine used in the current standard of care—Pegylated Interferon-alfa (Peg-IFN)—can cost as much as $18,000 USD in these countries for a 48-week course of treatment. For those who cannot afford it, this price tag may mean death.

In this new report, Hepatitis C Treatment: Price, Profits, and Barriers to Access, we examine the difference in price of a 48-week course of hepatitis C treatment in low- and middle-income countries, and detail breakthroughs that have been made in countries like Egypt and Thailand to negotiate lower prices and increase access to this lifesaving medicine.

Read more

Subscribe to updates about Open Society’s work around the world